About Regenxbio (NASDAQ:RGNX)
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$10.39 million
Price / Sales91.14
Price / CashN/A
Book Value$5.88 per share
Price / Book5.17
Return on Equity-36.48%
Return on Assets-34.17%
Regenxbio (NASDAQ:RGNX) Frequently Asked Questions
What is Regenxbio's stock symbol?
Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."
How were Regenxbio's earnings last quarter?
Regenxbio Inc (NASDAQ:RGNX) posted its earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.20. The biotechnology company had revenue of $2.04 million for the quarter. Regenxbio had a negative net margin of 704.02% and a negative return on equity of 36.48%. View Regenxbio's Earnings History.
When will Regenxbio make its next earnings announcement?
Where is Regenxbio's stock going? Where will Regenxbio's stock price be in 2018?
7 brokerages have issued 1-year price objectives for Regenxbio's shares. Their forecasts range from $25.00 to $85.00. On average, they anticipate Regenxbio's share price to reach $41.14 in the next year. View Analyst Ratings for Regenxbio.
What are Wall Street analysts saying about Regenxbio stock?
Here are some recent quotes from research analysts about Regenxbio stock:
- 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (3/16/2018)
- 2. Chardan Capital analysts commented, "We have long highlighted the importance of vector science for the progress in GT; and, we see Commissioner Gottlieb’s comments as highly supportive of our views. We again highlight REGENXBIO (Buy) (a Chardan Top Pick for 2017, and our Gene Therapy Top Pick) as the best way to play the emergence of in vivo GT, due to the company’s: (1) rights to 100+ vectors, (2) partnerships with 10 companies, (3) 25 or so internal and external product candidates, over 10 of which are in clinical development, and (4) abundance of important 2017 catalysts, which to us represent upside options." (12/11/2017)
Are investors shorting Regenxbio?
Regenxbio saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,309,082 shares, an increase of 65.5% from the January 31st total of 1,394,912 shares. Based on an average trading volume of 282,875 shares, the short-interest ratio is presently 8.2 days. Currently, 8.5% of the company's shares are short sold.
Who are some of Regenxbio's key competitors?
Some companies that are related to Regenxbio include Cambrex (CBM), Clinigen Group (CLIGF), Aimmune Therapeutics (AIMT), Editas Medicine (EDIT), Myokardia (MYOK), Intercept Pharmaceuticals (ICPT), Enanta Pharmaceuticals (ENTA), Atara Biotherapeutics (ATRA), ImmunoGen (IMGN), Innoviva (INVA), Radius Health (RDUS), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), Endo International (ENDP), Impax Laboratories (IPXL), Iovance Biotherapeutics (IOVA), Zogenix (ZGNX) and Xencor (XNCR).
Who are Regenxbio's key executives?
Regenxbio's management team includes the folowing people:
- Donald J. Hayden Jr., Independent Chairman of the Board (Age 61)
- Kenneth T. Mills, President, Chief Executive Officer, Executive Director (Age 42)
- Vittal K. Vasista, Chief Financial Officer (Age 49)
- Patrick J. Christmas, Senior Vice President, General Counsel (Age 46)
- Curran M. Simpson, Senior Vice President - Technical Operations (Age 55)
- Olivier Danos Ph.D., Chief Scientific Officer (Age 59)
- Stephen Yoo M.D., Chief Medical Officer (Age 39)
- Allan M. Fox, Director (Age 69)
- Daniel J. Abdun-Nabi, Independent Director (Age 57)
- Luke M. Beshar CPA, Independent Director (Age 59)
Who owns Regenxbio stock?
Regenxbio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.33%), RTW Investments LP (5.01%), Redmile Group LLC (4.58%), Perceptive Advisors LLC (4.56%), Citadel Advisors LLC (3.17%) and Franklin Resources Inc. (2.80%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Fmr Llc, Kenneth T Mills, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.
Who sold Regenxbio stock? Who is selling Regenxbio stock?
Regenxbio's stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Redmile Group LLC, Ascend Capital LLC, Perceptive Advisors LLC, Franklin Resources Inc., Deutsche Bank AG, Goldman Sachs Group Inc. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for Regenxbio.
Who bought Regenxbio stock? Who is buying Regenxbio stock?
Regenxbio's stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Artal Group S.A., Two Sigma Investments LP, Royce & Associates LP, Hudson Bay Capital Management LP, Iguana Healthcare Management LLC, RTW Investments LP and Sphera Funds Management LTD.. View Insider Buying and Selling for Regenxbio.
How do I buy Regenxbio stock?
Shares of Regenxbio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regenxbio's stock price today?
One share of Regenxbio stock can currently be purchased for approximately $30.40.
How big of a company is Regenxbio?
Regenxbio has a market capitalization of $946.81 million and generates $10.39 million in revenue each year. The biotechnology company earns $-73,160,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Regenxbio employs 139 workers across the globe.
How can I contact Regenxbio?
Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for Regenxbio (RGNX)MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Regenxbio (NASDAQ:RGNX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.86||2.86||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$41.14||$41.00||$43.17||$41.67|
|Price Target Upside: ||35.34% upside||53.27% upside||35.96% upside||83.96% upside|
Regenxbio (NASDAQ:RGNX) Consensus Price Target History
Regenxbio (NASDAQ:RGNX) Analyst Ratings History
(Data available from 3/18/2016 forward)
Regenxbio (NASDAQ:RGNX) Earnings History and Estimates Chart
Regenxbio (NASDAQ RGNX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/6/2018||Y 2017||($0.71)||($0.51)||$2.04 million||View||Listen|
|11/8/2017||Q3 2017||($0.71)||($0.67)||$1.34 million||View||N/A|
|8/8/2017||Q2 2017||($0.81)||($0.47)||$6.56 million||View||Listen|
|5/9/2017||Q1 2017||($0.76)||($0.82)||$0.46 million||View||Listen|
|3/7/2017||Y 2016||($0.75)||($0.74)||$1.70 million||View||Listen|
|11/9/2016||Q3 2016||($0.60)||($0.69)||$0.13 million||View||N/A|
|8/9/2016||Q2 2016||($0.52)||($0.55)||$2.38 million||View||N/A|
|3/3/2016||Q415||($0.34)||($0.20)||$1.23 million||$4.40 million||View||N/A|
Regenxbio (NASDAQ:RGNX) Earnings Estimates
Current Year EPS Consensus Estimate: $-2.44 EPS
Next Year EPS Consensus Estimate: $-3.26 EPS
Dividend History for Regenxbio (NASDAQ:RGNX)
No dividend announcements for this company have been tracked by MarketBeat.com
Regenxbio (NASDAQ RGNX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.00%
Institutional Ownership Percentage: 69.22%
Regenxbio (NASDAQ RGNX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/13/2018||Curran Simpson||SVP||Sell||25,000||$33.00||$825,000.00|| |
|2/20/2018||Kenneth T Mills||Insider||Sell||10,000||$26.56||$265,600.00||238,530|| |
|1/22/2018||Kenneth T Mills||Insider||Sell||10,000||$27.33||$273,300.00||248,530|| |
|1/16/2018||Vittal Vasista||CFO||Sell||5,000||$30.16||$150,800.00|| |
|12/22/2017||Curran Simpson||SVP||Sell||30,000||$33.03||$990,900.00||69,500|| |
|12/20/2017||Kenneth T Mills||Insider||Sell||10,000||$31.75||$317,500.00||108,530|| |
|12/19/2017||Vittal Vasista||CFO||Sell||5,000||$30.00||$150,000.00||87,277|| |
|12/7/2017||Curran Simpson||SVP||Sell||21,890||$30.04||$657,575.60||41,390|| |
|12/4/2017||Curran Simpson||SVP||Sell||110||$30.00||$3,300.00||39,610|| |
|11/27/2017||Curran Simpson||SVP||Sell||2,000||$29.31||$58,620.00||41,500|| |
|11/20/2017||Kenneth T Mills||Insider||Sell||10,000||$27.71||$277,100.00|| |
|10/20/2017||Kenneth T Mills||Insider||Sell||10,000||$32.62||$326,200.00||98,730|| |
|10/16/2017||Vittal Vasista||CFO||Sell||5,000||$33.25||$166,250.00||92,283|| |
|10/11/2017||Donald J Hayden Jr||Director||Sell||20,000||$34.95||$699,000.00|| |
|9/27/2017||Donald J Hayden Jr||Director||Sell||20,000||$32.45||$649,000.00||20,000|| |
|9/20/2017||Kenneth T Mills||Insider||Sell||10,000||$29.33||$293,300.00||108,630|| |
|9/18/2017||Donald J Hayden Jr||Director||Sell||40,000||$28.70||$1,148,000.00||20,000|| |
|9/15/2017||Vittal Vasista||CFO||Sell||5,000||$27.39||$136,950.00||99,594|| |
|9/8/2017||Stephen Yoo||Insider||Sell||27,342||$25.00||$683,550.00||27,342|| |
|9/6/2017||Stephen Yoo||Insider||Sell||32,658||$25.00||$816,450.00||31,803|| |
|9/5/2017||Donald J Hayden Jr||Director||Sell||20,000||$24.95||$499,000.00||20,000|| |
|9/5/2017||Kenneth T Mills||Insider||Sell||10,500||$25.00||$262,500.00||118,530|| |
|8/21/2017||Kenneth T Mills||Insider||Sell||6,500||$20.05||$130,325.00||105,500|| |
|8/15/2017||Vittal Vasista||CFO||Sell||3,040||$21.09||$64,113.60||103,118|| |
|7/20/2017||Kenneth T Mills||Insider||Sell||6,500||$18.66||$121,290.00||112,000|| |
|7/17/2017||Vittal Vasista||CFO||Sell||3,100||$19.81||$61,411.00||108,423|| |
|6/20/2017||Kenneth T Mills||Insider||Sell||6,500||$19.68||$127,920.00||119,396|| |
|6/15/2017||Vittal Vasista||CFO||Sell||3,100||$18.75||$58,125.00||107,512|| |
|4/24/2017||Donald J Hayden Jr||Director||Sell||10,000||$20.98||$209,800.00||28,599|| |
|4/24/2017||Kenneth T Mills||Insider||Sell||15,440||$20.98||$323,931.20||126,395|| |
|4/24/2017||Vittal Vasista||CFO||Sell||3,100||$21.00||$65,100.00||114,039|| |
|5/17/2016||Fmr Llc||Insider||Sell||18,300||$12.41||$227,103.00|| |
|5/16/2016||Fmr Llc||Insider||Sell||16,030||$11.65||$186,749.50|| |
|5/12/2016||Fmr Llc||Insider||Sell||6,711||$10.85||$72,814.35|| |
|5/11/2016||Fmr Llc||Insider||Sell||25,132||$10.36||$260,367.52|| |
|5/9/2016||Fmr Llc||Insider||Sell||10,570||$9.94||$105,065.80|| |
|5/4/2016||Fmr Llc||Insider||Sell||1,896||$10.51||$19,926.96|| |
|5/3/2016||Fmr Llc||Insider||Sell||6,046||$10.76||$65,054.96|| |
|4/29/2016||Fmr Llc||Insider||Sell||4,723||$10.80||$51,008.40|| |
|4/28/2016||Fmr Llc||Insider||Sell||33,196||$11.23||$372,791.08|| |
|4/26/2016||Fmr Llc||Insider||Sell||9,188||$11.19||$102,813.72|| |
|4/22/2016||Fmr Llc||Insider||Sell||20,558||$11.30||$232,305.40|| |
|4/20/2016||Fmr Llc||Insider||Sell||13,189||$11.66||$153,783.74|| |
|4/18/2016||Fmr Llc||Insider||Sell||18,900||$11.75||$222,075.00|| |
|4/14/2016||Fmr Llc||Insider||Sell||27,036||$11.46||$309,832.56|| |
|9/22/2015||James E Flynn||Insider||Buy||175,000||$22.00||$3,850,000.00|| |
Regenxbio (NASDAQ RGNX) News Headlines
|Regenxbio (RGNX) Upgraded to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 16 at 6:24 AM
|Insider Selling: Regenxbio Inc (RGNX) SVP Sells 25,000 Shares of Stock|
www.americanbankingnews.com - March 15 at 7:46 PM
|Regenxbio (RGNX) PT Lowered to $35.00 at Morgan Stanley|
www.americanbankingnews.com - March 14 at 11:45 AM
|Regenxbio (RGNX) Upgraded at Zacks Investment Research|
www.americanbankingnews.com - March 10 at 9:54 PM
|Regenxbio (RGNX) Cut to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - March 10 at 2:33 PM
|Zacks: Brokerages Expect Regenxbio Inc (RGNX) to Announce -$0.69 EPS|
www.americanbankingnews.com - March 9 at 5:23 PM
|Regenxbio (RGNX) Posts Earnings Results, Beats Estimates By $0.28 EPS|
www.americanbankingnews.com - March 6 at 7:17 PM
|Regenxbio Q4 Earnings Outlook|
finance.yahoo.com - March 6 at 4:59 PM
|REGENXBIO, Inc. to Host Earnings Call|
finance.yahoo.com - March 6 at 4:59 PM
|Regenxbio Inc (RGNX) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - March 4 at 3:30 AM
|Regenxbio Inc (RGNX) Sees Significant Increase in Short Interest|
www.americanbankingnews.com - March 3 at 3:26 AM
|Regenxbio Inc (RGNX) Position Lifted by Hudson Bay Capital Management LP|
www.americanbankingnews.com - March 1 at 12:04 PM
|Ascend Capital LLC Sells 180,988 Shares of Regenxbio Inc (RGNX)|
www.americanbankingnews.com - March 1 at 4:42 AM
|REGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights|
finance.yahoo.com - February 27 at 5:14 PM
|Regenxbio (RGNX) Set to Announce Quarterly Earnings on Monday|
www.americanbankingnews.com - February 26 at 3:38 AM
|Kenneth T. Mills Sells 10,000 Shares of Regenxbio Inc (RGNX) Stock|
www.americanbankingnews.com - February 22 at 6:46 PM
|-$0.71 EPS Expected for Regenxbio Inc (RGNX) This Quarter|
www.americanbankingnews.com - February 20 at 11:16 PM
|Mizuho Initiates Coverage on Regenxbio (RGNX)|
www.americanbankingnews.com - February 12 at 8:28 PM
|Regenxbio Inc (NASDAQ:RGNX): Financial Strength Analysis|
finance.yahoo.com - February 12 at 4:20 PM
|BidaskClub Upgrades Regenxbio (RGNX) to Buy|
www.americanbankingnews.com - February 10 at 9:24 AM
|Regenxbio (RGNX) Reports Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD|
www.streetinsider.com - February 9 at 9:23 AM
|REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD|
finance.yahoo.com - February 8 at 4:14 PM
|REGENXBIO to Participate in Upcoming Investor Conferences|
finance.yahoo.com - February 8 at 8:46 AM
|Regenxbio Inc (RGNX) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - February 7 at 3:24 AM
|BidaskClub Lowers Regenxbio (RGNX) to Hold|
www.americanbankingnews.com - February 2 at 6:52 AM
|REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth Biotechnologies|
finance.yahoo.com - January 24 at 9:50 AM
|Vittal Vasista Sells 5,000 Shares of Regenxbio Inc (RGNX) Stock|
www.americanbankingnews.com - January 18 at 7:58 PM
|-$0.71 Earnings Per Share Expected for Regenxbio Inc (RGNX) This Quarter|
www.americanbankingnews.com - January 18 at 1:42 AM
|Regenxbio Inc (RGNX) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - January 13 at 4:01 AM
|Stocks With Rising Relative Price Strength: Regenxbio|
finance.yahoo.com - January 11 at 12:00 PM
|[$$] Gene-Therapy Update: Mixed Results Don't Dim Hopes|
finance.yahoo.com - January 8 at 3:44 PM
|REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy|
finance.yahoo.com - January 8 at 8:32 AM
|Here's Why Regenxbio Dropped as Much as 17.6% Today|
finance.yahoo.com - January 5 at 3:40 PM
|Raymond James Financial Reiterates Buy Rating for Regenxbio (RGNX)|
www.americanbankingnews.com - January 5 at 1:34 PM
|Analyzing Regenxbio (RGNX) and Its Rivals|
www.americanbankingnews.com - January 5 at 7:28 AM
|Regenxbio Inc (RGNX) Expected to Post Earnings of -$0.71 Per Share|
www.americanbankingnews.com - January 1 at 7:28 AM
|ETFs with exposure to REGENXBIO, Inc. : December 28, 2017|
finance.yahoo.com - December 28 at 5:00 PM
|Regenxbio Inc (RGNX) SVP Curran Simpson Sells 30,000 Shares|
www.americanbankingnews.com - December 28 at 3:42 PM
|Regenxbio Sees Unusually High Options Volume (RGNX)|
www.americanbankingnews.com - December 28 at 2:38 AM
|REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017|
finance.yahoo.com - December 27 at 11:18 AM
|Reviewing Regenxbio (RGNX) and Verastem (VSTM)|
www.americanbankingnews.com - December 25 at 1:18 PM
|Regenxbio (RGNX) Upgraded by BidaskClub to Strong-Buy|
www.americanbankingnews.com - December 22 at 6:13 PM
|Regenxbio Inc (RGNX) Insider Kenneth T. Mills Sells 10,000 Shares|
www.americanbankingnews.com - December 21 at 5:24 PM
|Regenxbio Shows Rising Price Performance With Jump To 93 RS Rating|
finance.yahoo.com - December 21 at 11:28 AM
|Regenxbio Inc (RGNX) CFO Vittal Vasista Sells 5,000 Shares|
www.americanbankingnews.com - December 20 at 6:04 PM
|REGENXBIO, Inc. is trading above its 50 day moving average : RGNX-US : December 20, 2017|
finance.yahoo.com - December 20 at 11:27 AM
|BRIEF-Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II|
www.reuters.com - December 19 at 3:38 PM
|Regenxbio Inc (RGNX) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - December 19 at 3:36 AM
| Analysts Expect Regenxbio Inc (RGNX) to Announce -$0.71 Earnings Per Share|
www.americanbankingnews.com - December 15 at 11:06 AM
|Reviewing Regenxbio (RGNX) and Its Competitors|
www.americanbankingnews.com - December 15 at 9:14 AM
Regenxbio (NASDAQ:RGNX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Regenxbio (NASDAQ:RGNX) Income Statement, Balance Sheet and Cash Flow Statement
Regenxbio (NASDAQ RGNX) Stock Chart for Sunday, March, 18, 2018